# Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

> **NCT00665106** · PHASE1 · COMPLETED · sponsor: **Santen SAS** · enrollment: 20 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** NOVA63035 "Corticosteroid"

## Key facts

- **NCT ID:** NCT00665106
- **Lead sponsor:** Santen SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00665106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00665106, "Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00665106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*